Market Overview

Piper Jaffray Reiterates Overweight Rating, $103 PT on Watson Pharmaceuticals

Related WPI
Watson Pharma Buys Uteron Pharma SA
UPDATE: Goldman Sachs Downgrades Watson Pharmaceuticals to Neutral on Limited Upside

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating and $103.00 price target on Watson Pharmaceuticals (NYSE: WPI).

Piper Jaffray noted, “On Monday, Mallinckrodt (Covidien's pharma business) became the first filer to gain approval of a Concerta generic. While the approval comes as a surprise to us, Watson had long ago set expectations that a second entrant to the Concerta market would happen in 2013. WPI's guidance had already reflected one additional competitor in 1Q13, and most Street estimates (including ours) factor in further competition beyond 2013. With other high-value generics providing significant contribution (i.e. Lidoderm, Adderall XR) or providing the potential for longer-term upside (e.g., Intuniv), we continue to believe WPI earnings are still likely to approach $10 per share by 2014. With a 2014 P/E of 9x in the context of numerous high-value generics opportunities and compelling synergies from the Actavis transaction, we believe WPI shares are valued attractively. We reiterate our Overweight rating and $103 price target.”

Watson Pharmaceuticals closed on Monday at $86.00.

Latest Ratings for WPI

DateFirmActionFromTo
Jan 2013Goldman SachsDowngradesBuyNeutral
Nov 2012Piper JaffrayUpgradesNeutralOverweight
Nov 2012Credit SuisseMaintainsOutperform

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (WPI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters